These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38815162)

  • 1. The Selective SIRT3 Inhibitor 3-TYP Represses Primary Myeloma Growth by Reducing c-Myc Stability.
    Zeng Y; Zhang Y; Cui Z; Mao J; Xu J; Yao R
    Chem Res Toxicol; 2024 Jun; 37(6):1062-1069. PubMed ID: 38815162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a Novel c-Myc Inhibitor 7594-0037 by Structure-Based Virtual Screening and Investigation of Its Anti-Cancer Effect on Multiple Myeloma.
    Yao R; Xie Y; Sun X; Zhang M; Zhou J; Liu L; Gao J; Xu K
    Drug Des Devel Ther; 2020; 14():3983-3993. PubMed ID: 33061303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a novel c-Myc inhibitor with antitumor effects on multiple myeloma cells.
    Yao R; Sun X; Xie Y; Sun X; Yao Y; Li H; Li Z; Gao J; Xu K
    Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30068698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel dual-targeting c-Myc inhibitor D347-2761 represses myeloma growth via blocking c-Myc/Max heterodimerization and disturbing its stability.
    Yao R; Zhang M; Zhou J; Liu L; Zhang Y; Gao J; Xu K
    Cell Commun Signal; 2022 May; 20(1):73. PubMed ID: 35619182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma.
    Venkata JK; An N; Stuart R; Costa LJ; Cai H; Coker W; Song JH; Gibbs K; Matson T; Garrett-Mayer E; Wan Z; Ogretmen B; Smith C; Kang Y
    Blood; 2014 Sep; 124(12):1915-25. PubMed ID: 25122609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addiction to c-MYC in multiple myeloma.
    Holien T; Våtsveen TK; Hella H; Waage A; Sundan A
    Blood; 2012 Sep; 120(12):2450-3. PubMed ID: 22806891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gamabufotalin triggers c-Myc degradation via induction of WWP2 in multiple myeloma cells.
    Yu Z; Li T; Wang C; Deng S; Zhang B; Huo X; Zhang B; Wang X; Zhong Y; Ma X
    Oncotarget; 2016 Mar; 7(13):15725-37. PubMed ID: 26894970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimyeloma activity of bromodomain inhibitors on the human myeloma cell line U266 by downregulation of MYCL.
    Suzuki K; Yamamoto K; Arakawa Y; Yamada H; Aiba K; Kitagawa M
    Anticancer Drugs; 2016 Sep; 27(8):756-65. PubMed ID: 27276402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.
    Lee HC; Wang H; Baladandayuthapani V; Lin H; He J; Jones RJ; Kuiatse I; Gu D; Wang Z; Ma W; Lim J; O'Brien S; Keats J; Yang J; Davis RE; Orlowski RZ
    Br J Haematol; 2017 Apr; 177(1):80-94. PubMed ID: 28369725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
    Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF
    Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity.
    Li S; Zhao C; Zhang G; Xu Q; Liu Q; Zhao W; James Chou C; Zhang Y
    Bioorg Chem; 2021 Nov; 116():105278. PubMed ID: 34474303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.
    Li J; Favata M; Kelley JA; Caulder E; Thomas B; Wen X; Sparks RB; Arvanitis A; Rogers JD; Combs AP; Vaddi K; Solomon KA; Scherle PA; Newton R; Fridman JS
    Neoplasia; 2010 Jan; 12(1):28-38. PubMed ID: 20072651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma.
    Matthews GM; Lefebure M; Doyle MA; Shortt J; Ellul J; Chesi M; Banks KM; Vidacs E; Faulkner D; Atadja P; Bergsagel PL; Johnstone RW
    Cell Death Dis; 2013 Sep; 4(9):e798. PubMed ID: 24030150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of Novel 11-Triazole Substituted Benzofuro[3,2-b]quinolone Derivatives as c-myc G-Quadruplex Specific Stabilizers via Click Chemistry.
    Zeng DY; Kuang GT; Wang SK; Peng W; Lin SL; Zhang Q; Su XX; Hu MH; Wang H; Tan JH; Huang ZS; Gu LQ; Ou TM
    J Med Chem; 2017 Jul; 60(13):5407-5423. PubMed ID: 28514170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of WNK1 as a therapeutic target to suppress IgH/MYC expression in multiple myeloma.
    Ye T; Mishra AK; Banday S; Li R; Hu K; Coleman MM; Shan Y; Chowdhury SR; Zhou L; Pak ML; Simone TM; Malonia SK; Zhu LJ; Kelliher MA; Green MR
    Cell Rep; 2024 May; 43(5):114211. PubMed ID: 38722741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiRNA-29a as a tumor suppressor mediates PRIMA-1Met-induced anti-myeloma activity by targeting c-Myc.
    Saha MN; Abdi J; Yang Y; Chang H
    Oncotarget; 2016 Feb; 7(6):7149-60. PubMed ID: 26771839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FGF Trapping Inhibits Multiple Myeloma Growth through c-Myc Degradation-Induced Mitochondrial Oxidative Stress.
    Ronca R; Ghedini GC; Maccarinelli F; Sacco A; Locatelli SL; Foglio E; Taranto S; Grillo E; Matarazzo S; Castelli R; Paganini G; Desantis V; Cattane N; Cattaneo A; Mor M; Carlo-Stella C; Belotti A; Roccaro AM; Presta M; Giacomini A
    Cancer Res; 2020 Jun; 80(11):2340-2354. PubMed ID: 32094301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wogonin inhibits multiple myeloma-stimulated angiogenesis via c-Myc/VHL/HIF-1α signaling axis.
    Fu R; Chen Y; Wang XP; An T; Tao L; Zhou YX; Huang YJ; Chen BA; Li ZY; You QD; Guo QL; Wu ZQ
    Oncotarget; 2016 Feb; 7(5):5715-27. PubMed ID: 26735336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
    Delmore JE; Issa GC; Lemieux ME; Rahl PB; Shi J; Jacobs HM; Kastritis E; Gilpatrick T; Paranal RM; Qi J; Chesi M; Schinzel AC; McKeown MR; Heffernan TP; Vakoc CR; Bergsagel PL; Ghobrial IM; Richardson PG; Young RA; Hahn WC; Anderson KC; Kung AL; Bradner JE; Mitsiades CS
    Cell; 2011 Sep; 146(6):904-17. PubMed ID: 21889194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Covalent CDK7 Inhibitor THZ1 Potently Induces Apoptosis in Multiple Myeloma Cells
    Zhang Y; Zhou L; Bandyopadhyay D; Sharma K; Allen AJ; Kmieciak M; Grant S
    Clin Cancer Res; 2019 Oct; 25(20):6195-6205. PubMed ID: 31358538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.